CTKB Earnings & Financial Statements
Cytek Biosciences, Inc.
$5.44
+$0.07(+1.40%)
66
Overall
60
Value
83
Tech
55
Quality
Market Cap
$696.71M
Volume
1.74M
52W Range
$3.31 - $6.18
Target Price
$5.56
CTKB earnings and financial statements: Cytek Biosciences, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
CTKB Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $201.49M | $200.45M | $193.01M | $164.04M | $127.95M |
| Cost of revenue | $97.03M | $89.35M | $83.59M | $63.06M | $48.81M |
| Operating income | -$40.38M | -$20.52M | -$27.84M | -$1.80M | $9.16M |
| EBITDA | -$17.39M | -$449.0K | -$4.41M | $9.41M | $8.92M |
| Net income | -$66.54M | -$6.02M | -$12.15M | $2.58M | $3.03M |
| EPS (diluted) | $-0.52 | $-0.05 | $-0.09 | $0.02 | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $461.54M | $499.50M | $494.46M | $519.48M | $463.31M |
| Total liabilities | $119.80M | $103.76M | $101.39M | $93.93M | $57.92M |
| Shareholders’ equity | $341.74M | $395.74M | $393.06M | $425.55M | $405.38M |
| Cash and equivalents | $90.85M | $98.72M | $167.30M | $296.60M | $364.62M |
| Long-term debt | $14.57M | $8.60M | $11.13M | $14.58M | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$4.69M | $25.38M | $5.28M | -$12.23M | $4.63M |
| Capital expenditure | -$3.94M | -$3.44M | -$4.83M | -$9.87M | -$4.36M |
| Free cash flow | -$8.88M | $21.65M | $454.0K | -$22.10M | $266.0K |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CTKB | $5.44 | +1.4% | 1.74M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |